131 related articles for article (PubMed ID: 38318884)
21. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
[TBL] [Abstract][Full Text] [Related]
22. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial.
Beeh KM; Scheithe K; Schmutzler H; Krüger S
Int J Chron Obstruct Pulmon Dis; 2024; 19():205-216. PubMed ID: 38249826
[TBL] [Abstract][Full Text] [Related]
23. Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Marshall J; Sharma A; Darken P; Ouwens M; Singh B; Tansey-Dwyer D
Adv Ther; 2023 May; 40(5):2549-2555. PubMed ID: 37004641
[No Abstract] [Full Text] [Related]
24. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Balmaceda C; Espinoza MA; Abbott T; Peters A
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):743-751. PubMed ID: 35176212
[TBL] [Abstract][Full Text] [Related]
27. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
[TBL] [Abstract][Full Text] [Related]
30. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
Schroeder M; Benjamin N; Atienza L; Biswas C; Martin A; Whalen JD; Izquierdo Alonso JL; Riesco Miranda JA; Soler-Cataluña JJ; Huerta A; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2020; 15():1621-1632. PubMed ID: 32764908
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
COPD; 2018; 15(4):334-340. PubMed ID: 30265816
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Halpin DMG; Kendall R; Shukla S; Martin A; Shah D; Midwinter D; Beeh KM; Kocks JWH; Jones PW; Compton C; Risebrough NA; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():2745-2755. PubMed ID: 36317185
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
Mehta R; Pefani E; Beerahee M; Brealey N; Barnacle H; Birk R; Zhu CQ; Lipson DA
J Clin Pharmacol; 2018 Nov; 58(11):1461-1467. PubMed ID: 29762864
[TBL] [Abstract][Full Text] [Related]
35. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
36. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA; Crim C; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Lettis S; Manchester P; Martin N; Midwinter D; Morris A; Pascoe SJ; Singh D; Wise RA; Martinez FJ
Am J Respir Crit Care Med; 2020 Jun; 201(12):1508-1516. PubMed ID: 32162970
[No Abstract] [Full Text] [Related]
37. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Tabberer M; Jones CE; Kilbride S; Halpin DMG; Lomas DA; Pascoe S; Singh D; Wise RA; Criner GJ; Lange P; Dransfield MT; Han MK; Martinez FJ; Kaisermann MC; Lipson DA
Adv Ther; 2020 Sep; 37(9):3775-3790. PubMed ID: 32647911
[TBL] [Abstract][Full Text] [Related]
38. The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
[TBL] [Abstract][Full Text] [Related]
39. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Bansal S; Anderson M; Anzueto A; Brown N; Compton C; Corbridge TC; Erb D; Harvey C; Kaisermann MC; Kaye M; Lipson DA; Martin N; Zhu CQ; Papi A
NPJ Prim Care Respir Med; 2021 May; 31(1):29. PubMed ID: 34035312
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
